https://doi.org/10.31288/oftalmolzh201445158

Expression of differentiation (Cl) 16, CD19) and activation markers (CD25, CD95) of peripheral blood lymphocytes of patients with malignant epithelial tumors of the eyelid skin without and recurrence of tumors in follow-up dynamics

I. A. Safronenkova

State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)

Key words: malignant epithelial tumors of the eyelid skin, recurrence, immunologic status of lymphocyte markers (CD 16 +, CD 19 +, CD25, CD95).

Introduction. Immunological status of patients with malignant epithelial tumors (MET) of the eyelid skin during radiocryogenic treatment is of complex and com­bined character, on the one hand — the development of immunosuppression in­duced by the neoplastic process, and on the other hand — immunomodulation antitumor immune response under the influence of medical factors. Control of its restoration during cancer treatment and follow-up are studied insufficiently. Purpose. To explore the dynamics of the phenotypes of peripheral blood lympho­cytes by expression of differentiation (CD 16 +, CD 19 +) and activation (CD25 +, CD95 +) markers in patients with MET of the eyelid skin without and with recurrence of cancer.

Materials and methods. The study was conducted in 68 patients with MET of the eyelid skin of the stage T2a-3b NO MO. There were 29 men (42.6 %), and 39 (57.4 %) women. The control group consisted of 28 apparently healthy individuals aged 64.0+9.91 there were 12 men (46.4 %), and 16 (53,6 %) women. The phenotypic composition of the peripheral blood lymphocytes was assessed using specific McABpanel (CD16 +, CD19 +, CD25, CD95).

Results. Relative content (CD 19 +) in the tested group was significantly increased compared with controls 1.3 times (p = 0.01, 0.02 respectively) and remained high in the tested groups during the follow-up period. The relative content of the sub­population (CD 16 +) — lymphocytes in patients without tumor recurrence signifi­cantly increased from (11.5+0.57) % to (13.5+5.6) %(p = 0.03) in 6months and decreased to baseline values after 12 months. In the group with recurrent MET of the eyelid skin the relative level of expression (CD 16 +) in 6 and 12 months remained at the same level. Differences between the values of the level of expres­sion (CD 16 +) within a specified time of the follow-up in the groups under study were statistically significant (respectively p = 0.001, 0.002). The level of activa­tion of lymphocytes (CD25 +) in patients with MET of the eyelid skin in 6 and 12 months after treatment in the studied groups the relative terms (CD25+) in the group without recurrence tended to uniform reduction in this time and reached the control values. In the group of recurrence, a statistically significant decrease in these indicators (36.1+8.3) % to (21.0+5.78) % after 6 months (p = 0.000) and to (18.4+1.67) % (p = 0.001) — in 12 months. The group of patients without tumor recurrence tended to decrease the level of expression (CD95 +) after 6 months of treatment, whereas in the group with recurrent — content (CD95 +) remained at the same level with the baseline. After 12 months in the group without relapse, the relative content (CD95 +) in the peripheral blood was significantly decreased from (19.2+0.97) % to (11.6+0.39) % (p = 0.002), approaching control values. In contrast, in patients with relapses the expression (CD95 +) was significantly increased from (17.5+2.75) % to (22.9+1.11) % (p = 0.02) in a year after treat­ment. The difference of values of the expression level of the late marker of lympho­cyte activation (CD95 +) between the two treatment groups was also statistically significant (p = 0.000) at this time of the follow-up.

Conclusion. There were identified immunological markers (CD 16 +), (CD25 +) and (CD95 +), which in the monitoring conducted after the end of treatment, al­lowed to develop criteria for adverse in relation to tumor recurrence, prognosis of MET of the eyelid skin .

References

1.     Buiko AS. Malignant epithelial tumors of the eyelid skin:   incidence, risk factors, diagnosis, methods of treatment and their effectiveness. Oftalmol Zh. 2009;1- 2:49- 59. Russian.  
Crossref

2.     Buiko AS, Karpovskii YeYa, Safronenkova IA et al. Epi-  thelial tumors of the eyelids: cryodestruction or a scalpel? Oftalmol Zh. 1991;6:338- 44. Russian.    

3. Granov AM, Molchanov OE. Carcinogenesis and tumor immunology. Basic and clinical aspects. Voprosy onkologii.2008;54(4):401- 9. Russian. 

4.  Gluzman DF, Sklyarenko LM, Nadgornaya VA, Kryachok IA. Diagnostic immunology of tumors. Kiev: «Morion»; 2003.  6-15.

5.     Berzhnoi EE, Gnuchev NV, Georgiev GP et al. Molecular mechanisms of interaction between a tumor and immune system. Voprosy onkologii. 2008;54(6):669- 83. Russian.

6.     Kochenov VI. Cryological preventive oncology. Nizhnii Novgorod; 2003. 85 p.

7.     Stakheeva MN, Eidenzon DV, Slonimskaia YeM et al. The relationship of the immune system as an integrated whole with the clinical course of breast cancer. Sibirskii onkologicheskii zhurn. 2011;2:11-9. Russian.

8.     Apetoh L, Ghiringhelli F, Tesniere A et al. The interaction between HMGB1 and TLR4 dictates the outcome of an­ticancer chemotherapy and radiotherapy. Immunol. Rev. 2007;220:47-59.
Crossref

9.     Dranoff G. Immune recognition and tumor protection. Curr. Opin. Immunol. 2002;14(2):161-4.
Crossref

10.  Durairaj VD, Hink EM, Kahook MY et al. Mucinous ec-crine adenocarcinoma of the periocular region. Ophthal. Plast. Reconstr. Surg. 2006; 22(1):30- 5.
Crossref

11.  Koo L, Hatton MP, Rubin PA. «Pseudo-pseudochalazi-on»: giant chalazion mimicking eyelid neoplasm. Ophthal. Plast. Reconstr. Surg. 2005;21(5):391-2.
Crossref

12.  Lapka DV. Oncology today: Skin cancer. RN. 2000;63(7):32- 9.

13.  Mlecnik B, Bindea G, Pags F et al. Tumor immuno-surveillance in human cancers. Cancer Metastasis Rev.2011;30(1):5-12.
Crossref

14.  Spadaro M, Lanzardo S, Curcio C et al. Immunological inhibition of carcinogenesis. Cancer Immunol. Immunother. 2004;53:204-16.
Crossref

15.  Whiteside TL, Sung MW, Nagashima S et al. Human tu­mor antigen-specifc T-lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor ef­fects in vitro and in vivo. Clin cancer res. 1998;4:1135- 45.

16.  Zitvogel L, Apetoh L, Ghiringhelli F et al. Immunological aspects of cancer chemotherapy. Nature Reviews Immunology. 2008;8:59-73.
Crossref